FDA HAS RAMPED UP INSPECTIONS OF APIs--From FiercePharma Manufacturing: FDA warning to Abbey questions quality of API for sterile drugs Warning Letter lists repeat violation on water quality February 27, 2013 | By Eric Palmer Read more: FDA warning to Abbey questions quality of API for sterile drugs

The FDA says an active pharmaceutical ingredient maker in Philadelphia had yet to qualify that its purified water was in fact pure enough to make APIs two years after the agency noted a deficiency.
Abbey Color was told in a new warning letter posted to the FDA website this week that the agency is dissatisfied with the steps the company has taken to demonstrate that its water is suitable for use in manufacturing fluorescein USP, an API used in sterile drug products.
The inspection was conducted nearly a year ago, but the agency notes the company had promised in 2010 that it would make sure it had a reliable source of quality water. The most recent inspection found Abbey still passes spec endotoxin and total organic carbon test results. But inspectors found the operational parameters and effectiveness of an endotoxin removal unit had not been qualified and that Abbey was not monitoring the microbial and chemical attributes of the feed water.

The Biotech Primer: An insider's guide to the science driving the biotech and pharma industries

The Biotech Primer is a 200-page book featuring illustrations and a glossary of biotechnology terms. The text takes an in-depth look at the biotech industry, and in particular, the science that drives it. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come - and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends.Click here to buy today!

Sign up for our FREE newsletter for more news like this sent to your inbox!The FDA also came down on the company for not getting to the root cause of its water-supply issues. The manufacturer was further criticized for not setting up an adequate program to monitor API stability that would determine how the API should be stored.
The FDA has been ramping up inspections of APIs, and drugmakers using additional user fees that kicked in this year from generic manufacturers. But that work is being put to risk by looming across-the-board budget cuts from the current sequestration fight in Congress. A recent Congressional Budget Office (OMB) ruling said that user fees have to be cut as well. Regulatory Focus recently figured the cuts would mean a loss of about $200 million from the FDA's base budget and an estimated $112 million (annualized) in lost user fees.

- here's the warning letter

Read more: FDA warning to Abbey questions quality of API for sterile drugs - FiercePharma Manufacturing http://www.fiercepharmamanufacturing.com/story/fda-warning-abbey-questions-quality-api-sterile-drugs/2013-02-27#ixzz2MAm4Tpmh
Subscribe: http://www.fiercepharmamanufacturing.com/signup?sourceform=Viral-Tynt-FiercePharma Manufacturing-FiercePharma Manufacturing